期刊文献+

APE1在乳腺浸润性导管癌组织中的表达及其与预后的关系 被引量:1

Expression of APE1 in Breast Invasive Ductal Carcinoma and Its Relationship with Prognosis
下载PDF
导出
摘要 目的 了解脱嘌呤脱嘧啶核酸内切酶1(apurinic/apyrimidinic endonuclease 1,APE1)在乳腺浸润性导管癌组织中的表达情况,分析其与患者临床病理学参数之间的关系,探讨APE1蛋白表达与乳腺浸润性导管癌患者预后的关系. 方法 收集2002年1月~2012年12月东南大学附属江阴医院,第二军医大学附属长海医院经治的病理确诊的乳腺浸润性导管癌患者组织标本133例. 免疫组化法检测癌组织中APE1蛋白表达情况,并对其与临床病理参数的相关性进行分析. 生存分析采用Kaplan-Meier法,生存率比较采用Log-rank检验. 结果 133例患者失访14例,有效随访病例为119例. 患者中位年龄53岁, APE1蛋白阳性表达者96例(72.18%),阴性表达者37例(27.82%). APE1蛋白阳性表达和雌激素受体状态、Her2表达以及分子分型相关(P〈0.05),和年龄、肿瘤大小、有无淋巴结转移及组织学分级无关(P〉0.05). 生存分析提示APE1蛋白阴性患者的总生存时间(OS)优于阳性表达患者(P〈0.05). 结论 乳腺浸润性导管癌患者APE1蛋白表达与雌激素受体表达、Her2表达、分子分型相关. 相比于APE1阴性表达患者,阳性表达提示预后不良. Objective To understand the expression of APE1(apurinic/apyrimidinic endonuclease 1) in breast invasive ductal car-cinoma, analyze the intrinsic relationship between APE 1 expression and clinical pathological data , and evaluate the prognosis with Pro APE1.Methods Data from 133 patients diagnosed with breast invasive ductal carcinoma between January 2002 and December 2012 in Jiangyin Hospital Affiliated to Southeast University Medical School and Changhai Hospital of Second Military Medical University were re -viewed retrospectively .The expression of Pro APE1 was tested with Immunohistochemistry method , and a correlation analysis with patho-logical data was made .Survival function was done with Kaplan-Meier estimator, the survival distributions with Log-rank test was and compared.Results We missed 14 patients at the end of study and median age of the rest patients was 53 years old.96 of them manifes-ted positive Pro APE1 expressing (72.81%) and 37 of them manifested negative APE1 expressing (27.82%).Estrogen receptor positive (P〈0.05), HER-2 positive (P〈0.05), the molecular typing (P〈0.05) were statistically related to Pro APE1, while age (P〉0.05), size of tumor (P〉0.05), lymph node situation (P〉0.05), and historical stage (P〉0.05) were not significantly related .Sur-vival function shows that patients with negative Pro APE1 expressing had a longer OS than who had positive expressing (P〈0.05). Conclusion Expression of geneAPE1in invasive ductal breast cancer was associated to estrogen receptor , HER-2 and molecular typing . Compared with patients of APE 1 negative expressing , patients of APE1 positive expressing suggested a poor prognosis .
出处 《医学研究杂志》 2015年第10期114-117,共4页 Journal of Medical Research
关键词 脱嘌呤脱嘧啶核酸内切酶1 乳腺浸润性导管癌 预后 Apurinic/apyrimidinic endonuclease 1 (APEI) Breast invasive ductal carcinoma Prognosis
  • 相关文献

参考文献8

  • 1Yang S, Meyskens FL. Apurinic/ apyrimidinic endonucleaselredox effector factor - I (APE/Ref - I): a unique target for the prevention and treatment of human melanoma[J]. Antioxid Redox Signal ,2009, 11 (3) : 639 - 650.
  • 2Kr61 M, Pawlowski KM, Majchrzak K, et al. Why chemotherapy can fail[J] . PolishJournal of Veterinary Sciences, 2010, 13 (2) : 399 - 406.
  • 3Tell G, Quadrifoglio F , Tiribelli C, et al. The many functions of APEII Ref - I : not only a DNA repair enzyme[J]. Antioxid Redox Signal, 2009 , 11(3) : 601 - 620.
  • 4Luo M, He H, Kelley MR, et al. Redox regulation of DNA repair: implications for human health and cancer therapeutic development[J]. Antioxid Redox Signal, 2010,12(11) :1247 -1269.
  • 5Yang S, Irani K, Heffron SE, et al. Alterations in the expression of the apurinic/ apyrimidinic endonuclease - IIredox factor - I (APE/ Ref - I) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref -I inhibitor[J]. Mol Cancer Ther, 2005 ,4(12) : 1923 - 1935.
  • 6Sheng Q, Zhang Y, Wang R, et al. Prognostic significance of APE 1 cytoplasmic localization in human epithelial ovarian cancer[J]. Medical Oncology ,2012 ,29 (2) : 1265 - 1271.
  • 7KimJS, KimJM, Liang ZL, et al. Prognostic significance of human apurinic/ apyrimidinic endonuclease (APE/Ref - I) expression in rectal cancer treated with preoperative radiochemotherapy[J]. IntJ Radiat Oncol Biol Phys, 20 12,82 (1) : 130 - 137.
  • 8Burrell RA, McGranahan N, BartekJ, et al. The causes and consequences of genetic heterogeneity in cancer evolution[J]. Nature, 2013,501 (7467) :338 - 345.

同被引文献13

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部